Novartis maps $100M R&D complex in China

Novartis is building a $100 million research center in Shanghai, another example of the growing clout that China is demonstrating in the drug development industry. The 400,000-square-foot center will be Novartis' eighth R&D complex, employing some 400 scientists. Construction is set to begin the middle of next year. Analysts said that Novartis was lining up to take advantage of a lower-cost approach to developing new therapies.

- here's the AFP report on Novartis' China plans

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.